Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Total Current Liabilities (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Total Current Liabilities for 4 consecutive years, with $21.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 103.6% to $21.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.2 million through Dec 2025, up 103.6% year-over-year, with the annual reading at $21.2 million for FY2025, 103.6% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $21.2 million at LENZ Therapeutics, up from $16.3 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $21.2 million in Q4 2025, with the low at $7.7 million in Q3 2024.
  • Average Total Current Liabilities over 4 years is $12.8 million, with a median of $12.5 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 111.62% in 2025, while the deepest fall reached 54.63% in 2025.
  • Over 4 years, Total Current Liabilities stood at $13.0 million in 2022, then fell by 3.88% to $12.5 million in 2023, then fell by 17.0% to $10.4 million in 2024, then skyrocketed by 103.6% to $21.2 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $21.2 million, $16.3 million, and $10.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.